India mulls easier foreign direct investment in drug companies

Indian flag
India

India may allow foreign investors to buy up to 49% of existing drug companies as part of a push by Prime Minister Narendra Modi to liberalize investment rules. Investors would just have to notify the Reserve Bank of India on any transactions.

The tweak to make it easier to invest however has critics inside the industry and among civil groups concerned that manufacturers in the $20 billion-plus generic drug industry could potentially be squeezed, the Hindu BusinessLine reported.

India's Department of Industrial Policy and Promotion and the Finance Ministry are reviewing the issue as part of broader efforts to open up sectors of the economy to more foreign investment as was done with insurance last year with the cap nearly doubled from 26% to 49%. 

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

For the drug industry, India allows 100% ownership of so-called greenfield, or new projects. But foreign investment in existing drug companies needs a nod from the Foreign Investment Promotion Board, which in the past was granted in the case of Daiichi Sankyo's 2008 purchase of a majority in Ranbaxy Laboratories, among other deals.

Separately, India's Commerce and Industry Ministry has commissioned a study to assess the impact of foreign investment on the drug industry prompted by concerns that flows to date have been in existing companies instead of the hoped-for greenfield projects.

- here's the story from the Economic Times
- and one from the Hindu BusinessLine

Related Articles:
India plans drug industry foreign investment scorecard

Read more on

Suggested Articles

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

Astellas buys gene therapy player Audentes for $3 billion. Keytruda and Opdivo fail to win coverage in China. Hanmi inks I-O deal with Rapt.

It’s a familiar scene in the race onto China’s national reimbursement list: Drugmakers cut prices by an average 60.7% to win coverage.